Synthesis and biological activities of a novel class of azole-containing antifungal agents

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 12, 1996, Pages 1335-1338

  Liu, Lee Tai ^a   Lin, Ya Chuan ^a   Wang, Chia Lin J ^a   Lin, Mei Shey ^a   Yen, Su Chen ^a   Chen, Hsiao Jen ^a  

^a DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ENZYME INHIBITOR; FLUCONAZOLE; MICONAZOLE; MICROBIAL ENZYME; PYRROLE DERIVATIVE; STEROL; TETRAHYDROISOQUINOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG DESIGN; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; MOULD; MYCOSIS; TRICHOPHYTON MENTAGROPHYTES; YEAST;

ARTHRODERMA BENHAMIAE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CANDIDA; FILOBASIDIELLA NEOFORMANS; TRICHOPHYTON;

EID: 0001407716     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00222-3     Document Type: Article

References (17)

1. (a) Division of Natural Product and Medicinal Chemistry (b) Division of Drug Development
2. (a) Richardson, K.; Marriott, M. In Annual Reports in Medicinal Chemistry; Bailey, D. M., Ed.; Academic Press: N.Y., 1987; Vol. 22, Chapter 16, pp 159-167.
3. (b) Koltin, Y. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: N.Y., 1989; Vol. 25, Chapter 15, pp 141-148.
4. Barrett, J. F.; Klaubert, D. H. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: N.Y., 1992; Vol. 27, Chapter 15, pp 149-158.
5. Scrip's Antifungal Report: A Review of Progress in the Development of New Antifungals, PJB Publications: Surrey, UK, 1992.
6. Some of the conformationally constrained antifungal agents besides itraconazole and ketoconazole have been recently reported: (a) Konosu, T.; Tajima, Y.; Takeda, N.; Miyaoka, T.; Kasahara, M.; Yasuda, H.; Oida, S. Chem. Pharm. Bull. 1990, 38, 2476.
7. (b) Tsukuda, T.; Watanabe, M.; Ontsuka, H.; Fujimoto, Y.; Shimma, N. Bioorg. Med. Chem. Lett. 1994, 4, 733.
8. Bartroli, J.; Turmo, E.; Alguero, M.; Boncompte, E.; Vericat, M.; Garcia-Rafanell, J.; Forn, J. J. Med. Chem. 1995, 38, 3918 and references cited therein,
9. Fromtling, R. A.; Castaner, J. Drugs Future 1995, 20, 241.
10. Hayashi, K.; Ozakai, Y.; Nunami, K.; Yoneda, N. Chem. Pharm. Bull. 1983, 31, 312.
11. Shuman, R. T.; Rothenberger, R. B.; Campbell, C. S.; Smith, G. F.; Gifford-Moore, D. S.; Gesellchen, P. D. J. Med. Chem. 1993, 36, 314.
12. 4Cl: C 67.35; H 5.65; N 16.53. Found: C 67.73; H 5.75; N 16.42.
13. 9 The medium used was RPMI 1640 (pH 7.0). The incubation time and temperature were 48 hr and 37 °C separately. The MIC was defined as the lowest concentration of the drug that inhibited multiplication of the yeast and mycelial growth of the mold.
14. The MIC tests of compounds 7 and 13 were not detected because of their weak activity at a concentration of 50 μg/ml.
15. Shadomy, S.; Pfaller, M. In Manual of Clinical Microbiology, 5th ed.; Balows, A.; Hausler, W.; Herrmann, K.; Isenberg, H. D.; Shadomy, H. J., Ed.; American Society for Microbiology: Washington, D. C., 1991; Chapter 117, pp 1173-1181.
16. We thank Ms. Ying Chen for operating NMR spectrometers.
17. Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 12, pp. 1357-1360, 1996